SRPT
Sarepta Therapeutics Inc
NASDAQ · Biotechnology
$18.50
+1.47 (+8.63%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.85B | 1.33B | 612.32M | 549.72M | 591.13M |
| Net Income | 228.51M | 147.51M | -129,265,237 | -107,586,925 | -130,794,558 |
| EPS | — | — | — | — | — |
| Profit Margin | 12.4% | 11.8% | -21.1% | -19.6% | -22.1% |
| Rev Growth | +39.4% | +39.4% | -6.8% | +15.5% | +15.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 413.60M | 413.60M | 468.05M | 546.75M | 554.20M |
| Total Equity | 555.69M | 555.69M | 832.84M | 760.00M | 879.60M |
| D/E Ratio | 0.74 | 0.74 | 0.56 | 0.72 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 251.36M | 171.28M | -118,528,387 | -125,300,242 | -123,582,652 |
| Free Cash Flow | — | — | -131,122,574 | -79,607,758 | -118,891,652 |